<span style="margin-left: 0em;">HER inhibitor</span> <span style="margin-left: 1em;">EGFR inhibitor</span> <span style="margin-left: 2em;">cetuximab based chemotherapy</span> <span style="margin-left: 3em;">cetuximab plus platin plus 5FU <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab plus 5FU plus platin <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2) progression or deaths (PFS) (2) objective responses (ORR) (2) DOR (2) deaths (OS) (extension) (1) TRAE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) TRAE (grade 3-4) (2) TRAE leading to death (grade 5) (2) AE leading to death (grade 5) (2) AE (any grade) (1) AE (grade 3-4) (1) Nephritis TRAE (grade 3-4) (2) Uveitis TRAE (grade 3-4) (2) Myositis TRAE (grade 3-4) (2) Myocarditis TRAE (grade 3-4) (2) Rash TRAE (grade 3-4) (2) Diarrhoea TRAE (grade 3-4) (2) Colitis TRAE (grade 3-4) (2) Hepatitis TRAE (grade 3-4) (2) Weight decreased TRAE (grade 3-4) (2) Mucosal inflammation TRAE (grade 3-4) (2) Stomatitis TRAE (grade 3-4) (2) Blood creatinine increased TRAE (grade 3-4) (2) Infusion-related reactions TRAE (grade 3-4) (2) Blood and lymphatic system disorders TRAE (grade 3-4) (2) General disorders and administration site conditions TRAE (grade 3-4) (2) Metabolism and nutrition disorders TRAE (grade 3-4) (2) Hyperthyroidism TRAE (grade 3-4) (2) Thyroiditis TRAE (grade 3-4) (2) Fatigue TRAE (grade 3-4) (2) Nausea TRAE (grade 3-4) (2) Anaemia TRAE (grade 3-4) (2) Decreased appetite TRAE (grade 3-4) (2) Asthenia TRAE (grade 3-4) (2) Pneumonitis TRAE (grade 3-4) (2) Thrombocytopenia TRAE (grade 3-4) (2) Neutropenia TRAE (grade 3-4) (2) Vomiting TRAE (grade 3-4) (2) Constipation TRAE (grade 3-4) (2) Leucopenia TRAE (grade 3-4) (2) Hypophysitis TRAE (grade 3-4) (2) Adrenal insufficiency TRAE (grade 3-4) (2) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (2) Endocrine disorders TRAE (grade 3-4) (2) Severe skin reaction TRAE (grade 3-4) (2) Pancreatitis TRAE (grade 3-4) (2) Gastrointestinal disorders TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Gastrointestinal disorders AE (grade 3-4) (3) Rash AE (grade 3-4) (2) Increase AST AE (grade 3-4) (2) Weight decreased AE (grade 3-4) (2) Nausea AE (grade 3-4) (2) Vomiting AE (grade 3-4) (2) Abdominal pain AE (grade 3-4) (2) Fatigue AE (grade 3-4) (2) Asthenia AE (grade 3-4) (2) Decreased appetite AE (grade 3-4) (2) Dyspnoea AE (grade 3-4) (2) Stomatitis AE (grade 3-4) (2) Anaemia AE (grade 3-4) (2) Thrombocytopenia AE (grade 3-4) (2) Neutropenia AE (grade 3-4) (2) Diarrhoea AE (grade 3-4) (2) Hypertension AE (grade 3-4) (2) Febrile neutropenia AE (grade 3-4) (2) Blood and lymphatic system disorders AE (grade 3-4) (2) Leucopenia AE (grade 3-4) (2) Mucosal inflammation AE (grade 3-4) (2) General disorders and administration site conditions AE (grade 3-4) (2) Pneumonitis AE (grade 3-4) (2) Sepsis AE (grade 3-4) (2) Metabolism and nutrition disorders AE (grade 3-4) (2) Nervous system disorders AE (grade 3-4) (2) Renal and urinary disorders AE (grade 3-4) (2) Acute kidney injury AE (grade 3-4) (2) Respiratory, thoracic and mediastinal disorders AE (grade 3-4) (2) Skin and subcutaneous tissue disorders AE (grade 3-4) (2) Vascular disorders AE (grade 3-4) (2) Hypothyroidism AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 KEYNOTE-048 (P vs C ; all population), 2019 1 KEYNOTE-048 (PC vs C ; all population), 2019 cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.20 [1.01; 1.43] 1.20 [1.01;1.43]cetuximab plus platin plus 5FU vs. pembrolizumab alone
pembrolizumab alone better
1.20 [1.01; 1.43] cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.30 [1.07; 1.58] 1.30 [1.07;1.58]cetuximab plus platin plus 5FU vs. pembrolizumab plus 5FU plus platin
pembrolizumab plus 5FU plus platin better
1.30 [1.07; 1.58] pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.83 [0.70; 0.99] 0.83 [0.70;0.99]pembrolizumab alone vs. cetuximab plus platin plus 5FU
pembrolizumab alone better
0.83 [0.70; 0.99] pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.08 [0.83; 1.40] 1.08 [0.83;1.40]pembrolizumab alone vs. pembrolizumab plus 5FU plus platin
1.08 [0.83; 1.40] pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.77 [0.63; 0.94] 0.77 [0.63;0.94]pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin better
0.77 [0.63; 0.94] pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.93 [0.71; 1.20] 0.93 [0.71;1.20]pembrolizumab plus 5FU plus platin vs. pembrolizumab alone
0.93 [0.71; 1.20] cetuximab plus platin plus 5FU pembrolizumab alone pembrolizumab plus 5FU plus platin direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C cetuximab plus platin plus 5FU pembrolizumab alone pembrolizumab plus 5FU plus platin cetuximab plus platin plus 5FU --- 1.20 1.01; 1.431.30 1.07; 1.58pembrolizumab alone 0.83 0.70; 0.99--- 1.08 0.83; 1.40pembrolizumab plus 5FU plus platin 0.77 0.63; 0.940.93 0.71; 1.20---
pathologies: 102
- treatments: 875
result logic